-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2800 Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Health outcomes research, Clinical Research, Real-world evidence
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Jessica Lewis-Gonzalez, PharmD1*, Jonathon Cordova, MPhil2*, Huining Kang3*, Cecilia Y. Arana Yi, MD4, Ahmed Ibrahim5*, Patricia Greipp, DO6, Anand Ashwin Patel, MD7, Muriel Battaglia, MD8*, Anthony J. Perissinotti, PharmD9*, Bernard Lawrence Marini, PharmD10*, Martina Fraga, PharmD11*, Dale Bixby, MD, PhD12*, Kristen M. Pettit, MD12,13, Patrick W. Burke, MD12 and Charles Foucar, MD2

1University of New Mexico, Albuquerque, NM
2University of New Mexico School of Medicine, Albuquerque, NM
3University of New Mexico Health Sciences Center, Albuquerque, NM
4Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
5Mayo Clinic Arizona, Phoenix
6Division of Hematopathology, Mayo Clinic, Rochester, MN
7Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
8University of Chicago Medicine, Chicago
9University of Michigan Department of Pharmacy, Michigan Medicine, Ann Arbor, MI
10University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI
11University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor
12Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
13Rogel Cancer Center, University of Michigan, Ann Arbor, MI

Background:

Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a heterogenous subtype of B-ALL defined by the presence of gene expression profiling similar to Ph+ ALL in the absence of a BCR::ABL1 fusion. Ph-like ALL has lower response rates to standard frontline therapies and carries a poorer prognosis when compared to other B-ALL subtypes. However, the role in which specific patient characteristics may impact responses is not well described. Our aim for this retrospective study was to evaluate the characteristics and outcomes of a real-world cohort of patients (pts) with Ph-like ALL across multiple institutions, including describing key patient characteristics, treatments, and factors that may contribute to minimal residual disease (MRD) status and treatment response.

Methods:

We conducted a retrospective review of adult pts with Ph-like ALL diagnosed and treated at the University of New Mexico, Mayo Clinic Phoenix, University of Chicago, and University of Michigan between 1/1/18 – 2/1/2024. Pts were eligible if they carried a diagnosis of B-ALL, and were determined to have Ph-like ALL according to each institutional diagnostic algorithm. Descriptive statistics, ANOVA, and Fisher's exact test were employed to summarize various clinical characteristics and their associations. Cox regression analysis was utilized to estimate the median survival time and assess the relationship between clinical characteristics and survival outcomes, including overall survival and progression-free survival. All statistical analyses were conducted using the R statistical software.

Results:

67 pts were identified with a median age of 34.2 (IQR 28.5) and 35.8% were female. Twenty-eight pts identified as Hispanic or Latino (H/L) (43.1%), 25 (38.5%) identified as non-Hispanic White/Caucasian (NHW), 10 (15.4%) as American Indian/Alaska Native (AI/AN), and 2 (3.1%) as Asian/Pacific Islander. Thirteen pts (19.4%) had central nervous system (CNS) involvement at diagnosis, 22.4% of pts had extramedullary disease, and, in those who had NGS or cytogenomic microarray testing (n=49), 51% had an identified mutation/deletion in IKZF1.

Initial treatment varied widely with pts receiving most commonly: Children’s Oncology Group (COG) protocols (22.4%), CALGB 10403 (22.4%), HyperCVAD (11.9%), and CALGB 8811 (10.4%). Fifty-eight percent achieved a CR/CRi and 21% were refractory to initial therapy. Thirteen percent of pts received a Jak inhibitor and 6% of pts were treated with a TKI. Thirty pts (50.8%) underwent allogeneic stem cell transplant, with 8 of those pts (26.7%) experiencing a relapse post-transplant. Nine pts (13.4%) underwent treatment with CAR-T therapy with few pts experiencing grade 2 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Pts with CNS disease at diagnosis were less likely to achieve a CR/CRi compared to those without CNS disease at diagnosis (33.3% vs 64.0%; p=0.12). Pts identifying as AI/AN were more likely to be refractory to their first treatment compared to other racial/ethnic groups (75%, p=0.002).

Forty two percent of pts never achieved MRD negativity (< 0.01% by flow cytometry) during treatment; pts identifying as H/L and AI/AN had a higher rate of MRD positivity after induction compared to NHW pts (56% and 70% vs. 25%; p=0.02). In pts with IKZF1 mutation, 57.1% did not achieve MRD negativity compared to 21.7% in pts without a mutation (p=0.029).

The median overall survival (OS) was 66.3 months (mos) and the median progression-free survival (PFS) was 15.7 mos. Pts who did not achieve MRD negativity after initial treatment had shorter OS compared to those who did achieve MRD negativity, 33.9 mos vs 66.3 mos (p=0.086). Progression-free survival (PFS) was significantly shorter for patients who did not achieve MRD negativity after initial treatment compared to those who did, 3.9 mos vs 43.9 mos (p=0.001). PFS was shorter in pts who identify as AI/AN compared to H/L and NHW pts (2 mos vs 35.7 mos and 35.7 mos; p=0.046).

Conclusion:

Pts with Ph-like ALL experience poor response rates to therapies used to treat B-ALL, highlighting the urgent need for novel therapies and treatment strategies. We identified race/ethnicity and CNS disease at diagnosis as risk factors for poor treatment response. In addition, race/ethnicity and the presence of an IKZF1 mutation was associated with worse rates of MRD negativity during treatment.

Disclosures: Patel: Bristol Myers Squibb: Honoraria; Sumitomo: Research Funding; Pfizer: Research Funding; Sobi: Honoraria; AbbVie: Honoraria; Kronos Bio: Research Funding. Pettit: Imago: Research Funding; Blueprint Medicines: Research Funding; Sierra Oncology: Consultancy; Protagonist Therapeutics: Consultancy, Research Funding; PharmaEssentia: Consultancy; Incyte: Consultancy; AbbVie: Consultancy, Research Funding; Kura Oncology: Research Funding; BMS: Research Funding; Merck: Research Funding. Foucar: Novartis: Research Funding.

*signifies non-member of ASH